Drugs / imneskibart
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05267626 | Apr 2022 → Jun 2026 overdue | cutaneous melanoma, metastatic malignant neoplasm, non-small cell lung carcinoma | Aulos Bioscience, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | imneskibart | “This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in...” NCT05267626 ↗ |
| Known as | AU-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05267626 ↗ |
| Action | Inhibit | “AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding” NCT05267626 ↗ |
| Modality | Monoclonal antibody | “AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding” NCT05267626 ↗ |
| Target | IL2 | “AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding” NCT05267626 ↗ |